HER2低表达乳腺癌研究进展

doi:10.3760/cma.j.cn371439-20220609-00099

摘要/Abstract

摘要：

人表皮生长因子受体2（HER2）低表达乳腺癌具有较为独特的生物学行为,与HER2零表达乳腺癌相比,在分子分型与基因表达方面存在显著差异。以T-DXd为代表的新型抗体药物偶联物为HER2低表达乳腺癌患者提供了新的治疗选择,相关临床试验在持续开展中。目前,HER2低表达与乳腺癌患者预后的关系尚存争议。对HER2低表达乳腺癌的深入研究将有助于进一步改善该类乳腺癌患者的临床结局。

关键词: 乳腺肿瘤, 预后, 治疗学, 人表皮生长因子受体2低表达

Abstract:

Breast cancer with low expression of human epidermal growth factor receptor 2 （HER2） has unique biological behaviors. Compared with HER2-zero breast cancer, there are significant differences in molecular subtype and gene expression between the two categories of breast cancer. Novel antibody-drug conjugates represented by T-DXd provide a new treatment option for patients with HER2-low breast cancer, and relevant clinical trials are continuing. At present, the relationship between HER2-low status and prognosis of breast cancer patients remains controversial. In-depth research into HER2-low breast cancer will help further improve clinical outcomes for this population.

Key words: Breast neoplasms, Prognosis, Therapeutics, Low expression of human epidermal growth factor receptor 2

徐航程, 吴云, 王佳玉. HER2低表达乳腺癌研究进展[J]. 国际肿瘤学杂志, 2022, 49(9): 513-516.

Xu Hangcheng, Wu Yun, Wang Jiayu. Research progress of breast cancer with low HER2 expression[J]. Journal of International Oncology, 2022, 49(9): 513-516.

参考文献 34

[1]	Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up[J]. J Clin Oncol, 2021, 39(13): 1448-1457. DOI: 10.1200/JCO.20.01204. doi: 10.1200/JCO.20.01204 pmid: 33539215
[2]	Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (Cleopatra): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4): 519-530. DOI: 10.1016/S1470-2045(19)30863-0. doi: S1470-2045(19)30863-0 pmid: 32171426
[3]	Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962. DOI: 10.1200/JCO.19.02488. doi: 10.1200/JCO.19.02488 pmid: 32330069
[4]	Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ⅰb study[J]. J Clin Oncol, 2020, 38(17): 1887-1896. DOI: 10.1200/JCO.19.02318. doi: 10.1200/JCO.19.02318
[5]	Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer[J]. NPJ Breast Cancer, 2021, 7(1): 1. DOI: 10.1038/s41523-020-00208-2. doi: 10.1038/s41523-020-00208-2
[6]	Jacot W, Maran-Gonzalez A, Massol O, et al. Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers[J]. Cancers (Basel), 2021, 13(23): 6059. DOI: 10.3390/cancers13236059. doi: 10.3390/cancers13236059
[7]	Mutai R, Barkan T, Moore A, et al. Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer[J]. Breast, 2021, 60: 62-69. DOI: 10.1016/j.breast.2021.08.016. doi: 10.1016/j.breast.2021.08.016 pmid: 34481367
[8]	Zhang H, Katerji H, Turner BM, et al. HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles[J]. Mod Pathol, 2022, 35(8): 1075-1082. DOI: 10.1038/s41379-022-01019-5. doi: 10.1038/s41379-022-01019-5
[9]	Guven DC, Kaya MB, Fedai B, et al. HER2-low breast cancer could be associated with an increased risk of brain metastasis[J]. Int J Clin Oncol, 2022, 27(2): 332-339. DOI: 10.1007/s10147-021-02049-w. doi: 10.1007/s10147-021-02049-w
[10]	Eggemann H, Ignatov T, Burger E, et al. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer[J]. Endocr Relat Cancer, 2015, 22(5): 725-733. DOI: 10.1530/ERC-15-0335. doi: 10.1530/ERC-15-0335
[11]	Rossi V, Sarotto I, Maggiorotto F, et al. Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer[J]. Oncologist, 2012, 17(11): 1418-1425. DOI: 10.1634/theoncologist.2012-0194. doi: 10.1634/theoncologist.2012-0194 pmid: 22951668
[12]	Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials[J]. Lancet Oncol, 2021, 22(8): 1151-1161. DOI: 10.1016/S1470-2045(21)00301-6. doi: 10.1016/S1470-2045(21)00301-6 pmid: 34252375
[13]	Rosso C, Voutsadakis IA. Characteristics, clinical differences and outcomes of breast cancer patients with negative or low HER2 expression[J]. Clin Breast Cancer, 2022, 22(4): 391-397. DOI: 10.1016/j.clbc.2022.02.008. doi: 10.1016/j.clbc.2022.02.008 pmid: 35337735
[14]	Horisawa N, Adachi Y, Takatsuka D, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status[J]. Breast Cancer, 2022, 29(2): 234-241. DOI: 10.1007/s12282-021-01303-3. doi: 10.1007/s12282-021-01303-3
[15]	de Moura Leite L, Cesca MG, Tavares MC, et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer[J]. Breast Cancer Res Treat, 2021, 190(1): 155-163. DOI: 10.1007/s10549-021-06365-7. doi: 10.1007/s10549-021-06365-7
[16]	Xu H, Han Y, Wu Y, et al. Clinicopathological characteristics and prognosis of HER2-low early-stage breast cancer: a single-institution experience[J]. Front Oncol, 2022, 12: 906011. DOI: 10.3389/fonc.2022.906011. doi: 10.3389/fonc.2022.906011
[17]	Agostinetto E, Rediti M, Fimereli D, et al. HER2-low breast cancer: molecular characteristics and prognosis[J]. Cancers (Basel), 2021, 13(11): 2824. DOI: 10.3390/cancers13112824. doi: 10.3390/cancers13112824
[18]	Zhang G, Ren C, Li C, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status[J]. BMC Med, 2022, 20(1): 142. DOI: 10.1186/s12916-022-02346-9. doi: 10.1186/s12916-022-02346-9
[19]	Miglietta F, Griguolo G, Bottosso M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer[J]. NPJ Breast Cancer, 2021, 7(1): 137. DOI: 10.1038/s41523-021-00343-4. doi: 10.1038/s41523-021-00343-4 pmid: 34642348
[20]	Tarantino P, Gandini S, Nicolò E, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer[J]. Eur J Cancer, 2022, 163: 35-43. DOI: 10.1016/j.ejca.2021.12.022. doi: 10.1016/j.ejca.2021.12.022 pmid: 35032815
[21]	Miglietta F, Griguolo G, Bottosso M, et al. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment[J]. NPJ Breast Cancer, 2022, 8(1): 66. DOI: 10.1038/s41523-022-00434-w. doi: 10.1038/s41523-022-00434-w pmid: 35595761
[22]	Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG oncology phase Ⅲ randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2[J]. J Clin Oncol, 2020, 38(5): 444-453. DOI: 10.1200/JCO.19.01455. doi: 10.1200/JCO.19.01455 pmid: 31821109
[23]	Corti C, Giugliano F, Nicolò E, et al. Antibody-drug conjugates for the treatment of breast cancer[J]. Cancers (Basel), 2021, 13(12): 2898. DOI: 10.3390/cancers13122898. doi: 10.3390/cancers13122898
[24]	Manich CS, O'shaughnessy J, Aftimos PG, et al. LBA15 primary outcome of the phase Ⅲ SYD985.002/TULIP trial comparing [vic-] trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer[J]. Ann Oncol, 2021, 32: S1288. DOI: 10.1016/j.annonc.2021.08.2088. doi: 10.1016/j.annonc.2021.08.2088
[25]	Banerji U, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study[J]. Lancet Oncol, 2019, 20(8): 1124-1135. DOI: 10.1016/S1470-2045(19)30328-6. doi: S1470-2045(19)30328-6 pmid: 31257177
[26]	Perez J, Garrigós L, Gion M, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond[J]. Expert Opin Biol Ther, 2021, 21(7): 811-824. DOI: 10.1080/14712598.2021.1890710. doi: 10.1080/14712598.2021.1890710 pmid: 33759669
[27]	Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20. DOI: 10.1056/NEJMoa2203690. doi: 10.1056/NEJMoa2203690
[28]	Barroso-Sousa R, Tolaney SM. Clinical development of new antibody-drug conjugates in breast cancer: to infinity and beyond[J]. BioDrugs, 2021, 35(2): 159-174. DOI: 10.1007/s40259-021-00472-z. doi: 10.1007/s40259-021-00472-z pmid: 33666903
[29]	Eiger D, Agostinetto E, Saúde-Conde R, et al. The exciting new field of HER2-low breast cancer treatment[J]. Cancers (Basel), 2021, 13(5): 1015. DOI: 10.3390/cancers13051015. doi: 10.3390/cancers13051015
[30]	Won HS, Ahn J, Kim Y, et al. Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society[J]. Breast Cancer Res, 2022, 24(1): 22. DOI: 10.1186/s13058-022-01519-x. doi: 10.1186/s13058-022-01519-x pmid: 35307014
[31]	Tan RSYC, Ong WS, Lee KH, et al. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis[J]. BMC Med, 2022, 20(1): 105. DOI: 10.1186/s12916-022-02284-6. doi: 10.1186/s12916-022-02284-6 pmid: 35296300
[32]	Hein A, Hartkopf AD, Emons J, et al. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status[J]. Eur J Cancer, 2021, 155: 1-12. DOI: 10.1016/j.ejca.2021.06.033. doi: 10.1016/j.ejca.2021.06.033 pmid: 34311211
[33]	Gampenrieder SP, Rinnerthaler G, Tinchon C, et al. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry[J]. Breast Cancer Res, 2021, 23(1): 112. DOI: 10.1186/s13058-021-01492-x. doi: 10.1186/s13058-021-01492-x pmid: 34906198
[34]	Li Y, Abudureheiyimu N, Mo H, et al. In real life, low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer: a study of the National Cancer Center, China[J]. Front Oncol, 2022, 11: 774577. DOI: 10.3389/fonc.2021.774577. doi: 10.3389/fonc.2021.774577